Yin G-Q, Jiang W-H, Wu P-Q, He C-H, Chen R-S, Deng L
Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4348-4353.
This study focuses on evaluating the clinical effects of sublingual dust mite drops for the treatment of allergic asthma in children.
156 pediatric patients with allergic rhinitis and asthma were randomly divided into control and observation groups (78 cases each). For the control group the standard global initiative for asthma (GINA) asthma control scheme was adopted; meanwhile, the observation group patients received the standard GINA combined with sublingual administration of dust mite drops, once per day, gradually increasing the dose to reach a high maintenance level. After six months the sublingual drops were stopped and then the effects of the treatments on both groups of patients were compared.
The symptoms of asthma and rhinitis in the daytime and nighttime for both groups decreased gradually with time. However, the observation group's outcome at the 6th, 12th and 24th month were significantly better than those of the control group (p < 0.05). Moreover, the FVC, FEV1 and PEF values of the two groups increased gradually, but those of the observation group improved more obviously (p < 0.05). The total effective rate of the observation group at the 6th and 24th months was significantly higher than that of the control group (p < 0.05). The contrast of complete and good control at 6 months had no statistical significance (p > 0.05). But at the 24th month, the observation group had significantly higher rates of complete and good control (p < 0.05). During the median time of sublingual administration of 20.3 months (ranging from 6 to 36 months), there were no evident adverse reactions. Finally, after the intervention, there were no significant differences between the IgE levels of the two groups (p > 0.05); however, the levels of IL-2 increased gradually and improved more in the observation group (p < 0.05).
The results of our study support the notion that sublingual administration of dust mite drops to treat allergic rhinitis and asthma can improve clinical symptoms, increase the efficiency rate and increase the serum IL-2 level, and does not cause an increase in adverse reactions or IgE levels in treated children.
本研究聚焦于评估舌下含服尘螨滴剂治疗儿童过敏性哮喘的临床效果。
156例患有过敏性鼻炎和哮喘的儿科患者被随机分为对照组和观察组（每组78例）。对照组采用标准的全球哮喘防治创议（GINA）哮喘控制方案；与此同时，观察组患者接受标准GINA方案并舌下含服尘螨滴剂，每日一次，逐渐增加剂量至维持高水平。6个月后停用舌下滴剂，然后比较两组患者的治疗效果。
两组患者白天和夜间的哮喘及鼻炎症状均随时间逐渐减轻。然而，观察组在第6、12和24个月时的结果显著优于对照组（p<0.05）。此外，两组的用力肺活量（FVC）、第1秒用力呼气容积（FEV1）和呼气峰流速（PEF）值均逐渐升高，但观察组改善更为明显（p<0.05）。观察组在第6和24个月时的总有效率显著高于对照组（p<0.05）。6个月时完全控制和良好控制的对比无统计学意义（p>0.05）。但在第24个月时，观察组的完全控制和良好控制率显著更高（p<0.05）。在舌下给药的中位时间20.3个月（范围为6至36个月）内，未出现明显不良反应。最后，干预后两组的免疫球蛋白E（IgE）水平无显著差异（p>0.05）；然而，白细胞介素-2（IL-2）水平逐渐升高，且观察组改善更明显（p<0.05）。
我们的研究结果支持以下观点，即舌下含服尘螨滴剂治疗过敏性鼻炎和哮喘可改善临床症状、提高有效率并提高血清IL-2水平，且不会导致治疗儿童出现不良反应增加或IgE水平升高。
Zotero 插件